ECSP066534A - DOSAGE FORMS OF CONTROLLED OXYCODONE, ORALS, ONCE A DAY - Google Patents

DOSAGE FORMS OF CONTROLLED OXYCODONE, ORALS, ONCE A DAY

Info

Publication number
ECSP066534A
ECSP066534A EC2006006534A ECSP066534A ECSP066534A EC SP066534 A ECSP066534 A EC SP066534A EC 2006006534 A EC2006006534 A EC 2006006534A EC SP066534 A ECSP066534 A EC SP066534A EC SP066534 A ECSP066534 A EC SP066534A
Authority
EC
Ecuador
Prior art keywords
profiles
dosage forms
orals
vivo
day
Prior art date
Application number
EC2006006534A
Other languages
Spanish (es)
Inventor
Stephen Hwang
Padmaja Shivanand
Nishit B Modi
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Publication of ECSP066534A publication Critical patent/ECSP066534A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

Se proveen formulaciones de oxicodona que producen perfiles de plasma en estado estable in vivo sustancialmente planos; los niveles de tolerancia relacionados con dichos perfiles y niveles de tolerancia relacionados con perfiles bifásicos no se muestran estadísticamente diferentes; los perfiles de plasma en estado estable in vivo sustancialmente planos se producen a través de formas de dosificación que tienen perfiles de liberación in vitro sustancialmente de orden cero; dichos perfiles de liberación producen bajos niveles de Cmax in vivo de dosis única los cuales pueden reducir la probabilidad de efectos secundarios adversos.Oxycodone formulations that produce substantially flat stable in vivo plasma profiles are provided; the tolerance levels related to said profiles and tolerance levels related to biphasic profiles are not statistically different; substantially flat in vivo stable plasma profiles are produced through dosage forms having substantially zero-order in vitro release profiles; such release profiles produce low levels of Cmax in vivo single dose which can reduce the likelihood of adverse side effects.

EC2006006534A 2003-10-29 2006-04-28 DOSAGE FORMS OF CONTROLLED OXYCODONE, ORALS, ONCE A DAY ECSP066534A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US51588003P 2003-10-29 2003-10-29

Publications (1)

Publication Number Publication Date
ECSP066534A true ECSP066534A (en) 2006-11-24

Family

ID=34549453

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2006006534A ECSP066534A (en) 2003-10-29 2006-04-28 DOSAGE FORMS OF CONTROLLED OXYCODONE, ORALS, ONCE A DAY

Country Status (14)

Country Link
EP (1) EP1677798A2 (en)
JP (1) JP2007509979A (en)
KR (1) KR20060108690A (en)
CN (1) CN1933837A (en)
AU (1) AU2004285547A1 (en)
BR (1) BRPI0415639A (en)
CA (1) CA2546691A1 (en)
EC (1) ECSP066534A (en)
IL (1) IL175193A0 (en)
MA (1) MA28215A1 (en)
NO (1) NO20062398L (en)
RU (1) RU2006118323A (en)
WO (1) WO2005041968A2 (en)
ZA (1) ZA200604310B (en)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE526950T1 (en) 1999-10-29 2011-10-15 Euro Celtique Sa CONTROLLED RELEASE HYDROCODONE FORMULATIONS
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
EP2283829A1 (en) 2000-10-30 2011-02-16 Euro-Celtique S.A. Controlled release hydrocodone formulations
US20110104214A1 (en) 2004-04-15 2011-05-05 Purdue Pharma L.P. Once-a-day oxycodone formulations
UA81224C2 (en) * 2001-05-02 2007-12-25 Euro Celtic S A Dosage form of oxycodone and use thereof
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
DE10336400A1 (en) 2003-08-06 2005-03-24 Grünenthal GmbH Anti-abuse dosage form
DE10361596A1 (en) 2003-12-24 2005-09-29 Grünenthal GmbH Process for producing an anti-abuse dosage form
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE102004032051A1 (en) 2004-07-01 2006-01-19 Grünenthal GmbH Process for the preparation of a secured against misuse, solid dosage form
DE102005005446A1 (en) 2005-02-04 2006-08-10 Grünenthal GmbH Break-resistant dosage forms with sustained release
DE102004032049A1 (en) 2004-07-01 2006-01-19 Grünenthal GmbH Anti-abuse, oral dosage form
DE102005005449A1 (en) 2005-02-04 2006-08-10 Grünenthal GmbH Process for producing an anti-abuse dosage form
SA07280459B1 (en) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. Tamper Resistant Oral Pharmaceutical Dosage Forms Comprising an Opioid Analgesic
DE102007011485A1 (en) 2007-03-07 2008-09-11 Grünenthal GmbH Dosage form with more difficult abuse
CA2713128C (en) 2008-01-25 2016-04-05 Gruenenthal Gmbh Pharmaceutical dosage form
JP2011511782A (en) 2008-02-12 2011-04-14 アボット・ラボラトリーズ Extended release hydrocodone acetaminophen and related methods and uses
BRPI0912014A2 (en) 2008-05-09 2019-03-06 Grünenthal GmbH A process for preparing an intermediate powder formulation and a final solid dosage form using a spray freeze step
RU2015138422A (en) 2009-07-22 2018-12-25 Грюненталь Гмбх STABLE DURING OXIDATION, STRONG-BREAKED DOSAGE FORM
CN102573805A (en) 2009-07-22 2012-07-11 格吕伦塔尔有限公司 Hot-melt extruded controlled release dosage form
US20110150989A1 (en) * 2009-12-22 2011-06-23 Mallinkckrodt Inc. Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans
EP2555756B1 (en) * 2010-04-07 2018-08-22 Lupin Limited Controlled release pharmaceutical compositions of tapentadol
NZ607392A (en) 2010-09-02 2015-03-27 Gruenenthal Chemie Tamper resistant dosage form comprising inorganic salt
BR112013005234A2 (en) 2010-09-02 2016-05-03 Gruenenthal Gmbh Tamper resistant dosage form comprising an anionic polymer.
PE20141638A1 (en) 2011-07-29 2014-11-22 Gruenenthal Chemie HANDLE PROOF TABLET PROVIDING IMMEDIATE DRUG RELEASE
RS56527B1 (en) 2011-07-29 2018-02-28 Gruenenthal Gmbh Tamper-resistant tablet providing immediate drug release
MX356421B (en) 2012-02-28 2018-05-29 Gruenenthal Gmbh Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer.
DK2838512T3 (en) 2012-04-18 2018-11-19 Gruenenthal Gmbh MANIPULATED AND DOSAGE DUMPED PHARMACEUTICAL DOSAGE FORM
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
AR096439A1 (en) 2013-05-29 2015-12-30 Gruenenthal Gmbh DOSAGE METHOD RESISTING TO INDEED USE CONTAINING ONE OR MORE PARTICLES
JP6445537B2 (en) 2013-05-29 2018-12-26 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Tamper-resistant dosage forms containing one or more particles
US10624862B2 (en) 2013-07-12 2020-04-21 Grünenthal GmbH Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
AU2014356581C1 (en) 2013-11-26 2020-05-28 Grunenthal Gmbh Preparation of a powdery pharmaceutical composition by means of cryo-milling
MX2016014738A (en) 2014-05-12 2017-03-06 Gruenenthal Gmbh Tamper resistant immediate release capsule formulation comprising tapentadol.
MX2016015417A (en) 2014-05-26 2017-02-22 Gruenenthal Gmbh Multiparticles safeguarded against ethanolic dose-dumping.
JP2018517676A (en) 2015-04-24 2018-07-05 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Anti-modification formulation with immediate release and resistance to solvent extraction
AU2016319203A1 (en) 2015-09-10 2018-02-22 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
CA3032233C (en) 2016-08-10 2021-09-14 F. Hoffmann-La Roche Ag Pharmaceutical compositions comprising akt protein kinase inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5914131A (en) * 1994-07-07 1999-06-22 Alza Corporation Hydromorphone therapy
UA81224C2 (en) * 2001-05-02 2007-12-25 Euro Celtic S A Dosage form of oxycodone and use thereof
DE60325715D1 (en) * 2002-04-29 2009-02-26 Alza Corp METHODS AND PHARMACEUTICAL FOR THE CONTROLLED RELEASE OF OXYCODONE
RU2004134728A (en) * 2002-05-31 2005-06-10 Алза Корпорейшн (Us) DOSED FORMS AND COMPOSITIONS FOR THE OSMOTIC DELIVERY OF VARIOUS DOSAGE OXYCODONE

Also Published As

Publication number Publication date
JP2007509979A (en) 2007-04-19
RU2006118323A (en) 2007-12-10
KR20060108690A (en) 2006-10-18
NO20062398L (en) 2006-07-27
AU2004285547A1 (en) 2005-05-12
IL175193A0 (en) 2008-04-13
CN1933837A (en) 2007-03-21
BRPI0415639A (en) 2006-12-12
MA28215A1 (en) 2006-10-02
CA2546691A1 (en) 2005-05-12
EP1677798A2 (en) 2006-07-12
WO2005041968A2 (en) 2005-05-12
WO2005041968A3 (en) 2006-06-22
ZA200604310B (en) 2007-11-28

Similar Documents

Publication Publication Date Title
BRPI0415639A (en) once daily controlled release oxycodone oral dosage forms
CR7500A (en) DOSAGE FORMS OF AZITROMICIDE WITH REDUCED SIDE EFFECTS
CR8767A (en) REPLACED INDAZOLS, COMPOSITIONS THAT CONTAIN THEM, PREPARATION PROCEDURE AND ITS USE
BR0309620A (en) Methods and dosage forms for controlled release of oxycodone
NO20076613L (en) Pharmaceutical Formulations and Their Use
CA2683786C (en) Use of tapentadol in the treatment of pain and with a reduced incidence of tapentadol-induced side-effects
PA8616201A1 (en) PHARMACEUTICAL COMPOSITIONS OF SUSTAINED LIBERATION
SV2003001493A (en) SUBSTITUTED INDAZOLS, COMPOSITIONS THAT CONTAIN THEM, MANUFACTURING AND USE PROCEDURE
HRP20060147B1 (en) CONTROLLED RELEASE THERAPY SYSTEM FOR Oral Use
BRPI0707612B8 (en) sealed vessel and liquid formulations contained therein
PA8559501A1 (en) PHARMACEUTICAL FORMULATIONS OF 5,7,14-TRIAZATETRACICLO [10.3.1.02,11.04,9] -HEXADECA-2 (11), 3,5,7,9-PENTAENO
ECSP055726A (en) STABILIZED PHARMACEUTICAL COMPOSITION CONTAINING BASIC EXCIPIENTS
AR047191A1 (en) METHODS OF TREATMENT OF HEPATIC FIBROSIS
TW200640497A (en) Pharmaceutical formulations and methods of use
AR035293A1 (en) OPHTHALMIC COMPOSITION.
CO6771406A2 (en) A combined composition
ATE505203T1 (en) PHARMACEUTICAL COMBINATION OF ALISKIREN AND VALSARTAN
MX2010004556A (en) Pharmaceutical formulation of clavulanic acid.
TW200744672A (en) Pharmaceutical formulations/composition of guanfacine suitable for single dose form administration daily
EA200970353A1 (en) COMBINED MEDICINE
TW200503785A (en) Dosage form containing (S)-pantoprazole as active ingredient
DK1220676T3 (en) Prevention of colorectal cancer
MX2009008813A (en) PHARMACEUTICAL COMPOSITION CONTAINING FLOROGLUCINOL AND PARACETAMOL.
EA200501565A1 (en) INTENDED FOR ORAL ADMINISTRATION MEDICINE FORM FOR PROTONE PUMP ANTAGONISTS
PL378106A1 (en) Method for producing a pharmaceutical composition in the form of fibrate-containing tablets and tablets produced by said method